Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Chimeric Therapeutics Ltd C.CHM


Primary Symbol: CHMMF

Chimeric Therapeutics Limited is an Australia-based clinical-stage cell therapy company. The Company is focused on the discovery, development, and commercialization of cell therapies for patients with cancer. Its pipeline includes CHM 1101 and CHM 2101. Its CHM 1101 (CLTX CAR-T) is a CAR-T therapy developed for the treatment of patients with solid tumors. CHM-1101 is being studied in a Phase 1B clinical trial in recurrent/ progressive glioblastoma. CHM 2101 is a third generation CDH17 CAR T, which is in preclinical development with a planned Phase I clinical trial in neuroendocrine tumors, colorectal, pancreatic and gastric cancer. Its pipeline also includes the CORE-NK platform, a clinically validated, off-the-shelf natural killer (NK) cell therapy platform to their portfolio (CHM 0201). The Company is also focused on the development of NK and CAR NK assets with plans for Phase 1B clinical trials in solid tumors and blood cancers.


OTCPK:CHMMF - Post by User

Post by LowMooron Jan 19, 2021 5:33pm
184 Views
Post# 32329602

Read. look at these guys..why I loaded up a month ago.

Read. look at these guys..why I loaded up a month ago.

VANCOUVER, BC , Sept. 28, 2020 /PRNewswire/ - Chemistree Technology Inc. (CSE: CHM) and (CSE: CHM.wt) (US OTCQB: CHMJF) (the "Company" or "Chemistree") is pleased to inform shareholders that Chemistree investee company Immunoflex Therapeutics ("ImmunoFlex") has announced the appointment of Dr David MacDonald to its executive team and established a Scientific Advisory Board to be headed by Dr. Vernon Oi.

Dr David MacDonald has an over 30-year record of achievement in drug development and leadership of biotech companies achieving important technical milestones for those businesses and meeting critical corporate objectives. Prior to ImmunoFlex, Dr MacDonald was at MSI Methylation Sciences Inc. a clinical-stage pharmaceutical company, leading the R&D efforts, focused on pharmaceutical product and clinical development. Dr MacDonald has also held leadership positions in a number of small and large pharma biotech companies during which he was accountable for a broad range of technical departments and stages of development covering basic research, IND-enabling studies, formulation, CMC, phase 1 and phase 2 clinical trials, intellectual property, and regulatory submissions and inspections. Dr MacDonald obtained his Ph.D. in Chemistry from the University of Alberta where his research was focused on enzymology.

Scientific Advisory Board

ImmunoFlex has also established a three-member scientific advisory, drawing on some of the most talented and experienced people in the bio-technology and immunology fields.

Dr. Vernon Oi, has been named Chair of the ImmunoFlex Scientific Advisory Board. Dr. Oi is a world-renowned Immunologist with over 200 peer reviewed publications and multiple patents. He received his bachelor's degree from Stanford University and doctoral degree from the Stanford University School of Medicine. In addition, he studied in the Department of Microbiology and Immunology at the University of California at Berkeley and the Medical Research Council and Agricultural Research Council in the UK before joining Stanford University's faculty in the Department of Genetics. Dr. Oi is an inventor on a key Stanford patent for functional antibodies, an invention used to produce drugs including Remicade (Johnson & Johnson), Synagis (MedImmune) and others. In 2019, functional antibody-based therapeutics generated over $150 billion in revenues globally.

Dr. Jian Han is a Hudson Alpha Institute for Biotechnology Faculty Investigator. Dr. Han has more than 30 years of experience developing molecular diagnostic technologies and products. He is interested in developing integrated solutions for molecular differential diagnosis and developing a technology platform that allows multiplex molecular differential diagnoses to be carried out in a fashion that is high throughput, semi-quantitative, automatic, and in a closed system. He studies the immunorepertoire of different autoimmune diseases and cancers using multiplex PCR and high-throughput gene sequencing. As the director of the R10K project, Dr. Han leads a team that is sequencing 10,000 samples and studying biomarkers for 100 diseases. He earned his MD from ShuZhou Medical College in China and his PhD in clinical molecular genetics from the University of Alabama at Birmingham.

Dr. Leonore (Lee) A. Herzenberg , is a Stanford Flow Cytometry Chair in Genetics, Stanford Professor of Genetics, and Stanford Professor of the Interdepartmental Program in Immunology. Dr. Herzenberg and her late husband Dr. Leonard (Len) A. Herzenberg made many seminal contributions to immunoglobulin heavy chain (IgH) genetics and to functional analyses and lineage studies of mouse and human B and T cells. Some of the Herzenbergs' "firsts" include the initial development of the Fluorescence Activated Cell Sorter (FACS), the development of the first monoclonal antibody reagents for FACS, and the continued development and improvement of computer support for the acquisition, analysis, display and storage of flow cytometry data. This technology is now being used to explore the recently developed humanized mouse model and to expand work conducted in other laboratories with human samples relevant to HIV and other diseases.

Chemistree President Karl Kottmeier commented, "These are great advancements for ImmunoFlex. Dr. MacDonald is a tremendously experienced scientist and a major addition to the ImmunoFlex management team. I am also very impressed with ImmunoFlex's ability to attract such experienced and highly regarded scientists to its new Scientific Advisory Board."


<< Previous
Bullboard Posts
Next >>